-
What Approval For Generic Copaxone Means For Mylan
Wednesday, October 4, 2017 - 8:27am | 330Read More...Shares of Mylan N.V. (NASDAQ: MYL) traded higher by more than 13 percent Wednesday morning after the U.S. Food and Drug Administration granted approval for the company's generic version of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s Copaxone. Copaxone, a therapy that is intended...
-
Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
Thursday, February 23, 2017 - 3:06pm | 615Read More...Offering its insight into the formulary coverage of multiple sclerosis drugs for 2017, Bernstein said in a note released on Thursday it sees stabilization of formulary coverage after a year of tightening in 2016. Treatment Options MS is a neurodegenerative disease affecting young adults,...
-
Lingo Failure Leads Citi To Downgrade Biogen
Wednesday, June 8, 2016 - 10:03am | 261Read More...Biogen Inc (NASDAQ: BIIB) announced that anti-Lingo failed both the primary and the secondary endpoints in its Phase 2 RRMS trial. Citi’s Robyn Karnauskas downgraded the rating on the company from Buy to Neutral, while lowering the price target from $345 to $295. Lingo Failure “While...
-
Synthetic Biologics Crashes Following Disappointing Phase 2 Results
Tuesday, February 2, 2016 - 2:36pm | 215Read More...Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, lost more than 16 percent and hit a new 52-week low of $1.17 on Tuesday after the company released results of an independent third party evaluation of its Phase 2 clinical trial. Synthetic Biologics's...
-
Acorda Therapeutics Could Be a Stock to Watch in 2013
Monday, February 4, 2013 - 4:21pm | 330Read More...Acorda Therapeutics (NASDAQ: ACOR) has been off to a hot start in 2013. The stock is already up around 16 percent on the year and shares are trading near 52-week high levels at roughly $29. The company has a market cap of $1.16 billion at current levels and the stock has risen over nine percent...
